ArticleRadiology case reports2026
Gradual spontaneous regression of hepatic hemangioma in a woman with surgical menopause: A decade of imaging follow-up.
Article in Radiology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Spontaneous regression of a giant hepatic hemangioma on serial MRI: A case report with 3-year follow-up.Radiology case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatic hemangiomas (HHs), the most common benign liver tumors, may grow, remain stable, or rarely regress spontaneously, with regression potentially associated with reduced estrogen levels. We report a 67-year-old woman with a large HH exhibiting gradual regression (∼3 mm/year) over a decade of imaging post-surgical menopause in 2010, without hormone replacement therapy. Serial computed tomography (CT) and ultrasound (US) from 2014 to 2025 showed an initial 5.4 cm lesion, hypoechoic on US due to early-stage (F0-F1) metabolic dysfunction-associated steatotic liver disease (MASLD; Fibrosis-4 index <1.3) but with classic CT features (discontinuous peripheral nodular enhancement, centripetal fill-in). By 2025, the lesion regressed in size to ∼2 cm, and loss of previously seen regions of enhancement suggesting sclerosing. This case highlights gradual HH regression years after menopause, emphasizes multimodal imaging for MASLD-related US atypia, and supports conservative management for asymptomatic cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.